BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Feb 3, 2017
Clinical News

SB204: Ph III NI-AC301 and NI-AC302 data

...in Japan to treat acne (see BioCentury, Jan. 23 ). Novan Inc. (NASDAQ:NOVN), Durham, N.C. Sato Pharmaceutical Co. Ltd....
...count and time to improvement in IGA Status: Phase III data Milestone: NA Jaime De Leon NVN1000 SB204 Novan Inc. Sato Pharmaceutical Co. Ltd. Androgen...
BioCentury | Jan 20, 2017
Company News

Novan, Sato deal

...29, 2016 ). Novan Inc. (NASDAQ:NOVN), Durham, N.C. Sato Pharmaceutical Co. Ltd. , Tokyo, Japan Business: Dermatology Nora Weintraub SB204 Novan Inc. Sato Pharmaceutical Co. Ltd....
Items per page:
1 - 3 of 3
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Feb 3, 2017
Clinical News

SB204: Ph III NI-AC301 and NI-AC302 data

...in Japan to treat acne (see BioCentury, Jan. 23 ). Novan Inc. (NASDAQ:NOVN), Durham, N.C. Sato Pharmaceutical Co. Ltd....
...count and time to improvement in IGA Status: Phase III data Milestone: NA Jaime De Leon NVN1000 SB204 Novan Inc. Sato Pharmaceutical Co. Ltd. Androgen...
BioCentury | Jan 20, 2017
Company News

Novan, Sato deal

...29, 2016 ). Novan Inc. (NASDAQ:NOVN), Durham, N.C. Sato Pharmaceutical Co. Ltd. , Tokyo, Japan Business: Dermatology Nora Weintraub SB204 Novan Inc. Sato Pharmaceutical Co. Ltd....
Items per page:
1 - 3 of 3